Pluristem Therapeutics Inc (PSTI)

[Scott999]

That's right Eichking. Nice to dream of getting to a point of selling something, as far out as that seems.

Looking into the CHA agreement again, it states the following.

"Under the terms of the agreement, Cha will perform and fund multiple clinical trials in South Korea for treating CLI and IC using PLX-PAD under the supervision of the Korea Food & Drug Administration"

What trials have they actually "funded" to potentially reap 50% stake in a JV? Looking at IC, they had 8 sites of the 30. Don't know if I would call that funding. How many of the 172 enrolled wen through Korea? Nothing at all for CLI. Will we have to give 50% for something they really weren't involved with, should we gain approval?

I'm sorry but between CHA and Sosei, they don't look like much to me. Feel free to try and change my mind. I realize partnering most likely necessary to gain access to these markets, but seems a pretty small amount for CHA to give up, to gain a 50% stake. We get a potential 30% in Japan if that ever happens.

I assume we paid for a vast majority of this trial, based solely on recruitment sites. So why did they do this partnership then. Again going back to risk, not much risked by CHA, but would be rewarded substantially if approval comes.

This imo, is just another one to be chalked up to experience, or lack thereof. Just like starting hip trial, then delay it 4 years before putting it back on the table. (Not on the table yet, but funding has come) or preeclampsia. Duschenes was another I think. MS, Lou Gehrig's, also come to mind. But could be wrong. I'm sure these preclinical trials aren't the cheapest things to do. All for what, to throw them on the back burner.

And now, oncology. Just seems to me they have spread themselves too thin chasing any potential treatment. Would have been better to focus on one or two, and get to the finish line.

Not much of anything this company does, makes much sense to me. ARS better come soon and better work out. Or I will be right there calling this company dead as well.